Skip to main
PEN

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 25%
Buy 13%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra Inc. is positioned for significant financial growth, supported by expectations of improving gross and operating margins, as well as above-average EPS growth relative to revenue increases. The company is projected to sustain mid-teens revenue growth over the next few years, with potential acceleration into the high-teens by 2026, driven by innovative product offerings and favorable market conditions. Additionally, Penumbra's leadership in the thrombectomy market, coupled with its anticipated neurovascular franchise expansion, underlines its attractiveness as a growth investment, especially as competition dynamics evolve.

Bears say

The analysis of Penumbra Inc. highlights several fundamental factors contributing to a negative outlook for the company's stock. Key concerns include potential setbacks in product launches, increased competition in the mechanical thrombectomy market, and the risk of unfavorable changes in reimbursement policies, all of which could adversely affect growth and revenue generation. Additionally, challenges in customer acquisition and dependency on successful regulatory approvals for new products further compound the uncertainties surrounding Penumbra's future financial performance.

Penumbra (PEN) has been analyzed by 16 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 13% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Buy based on their latest research and market trends.

According to 16 analysts, Penumbra (PEN) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $359.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $359.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.